Orexigen Therapeutics (OREX) Reports Q1 Loss of $4.67/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Orexigen Therapeutics (OREX) Reports Q1 Loss of $4.67/Share

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017

May 9, 2017 4:01 PM EDT

SAN DIEGO, May 9, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2017.

"During the first quarter of 2017, the team at Orexigen delivered dramatic growth of U.S. Contrave sales and a clear trend break from prior performance," said Mike Narachi, CEO of Orexigen. He continued, "Our commercial model continues to evolve, and we expect it to become increasingly effective and more efficient, which we believe positions Orexigen to deliver strong, sustainable growth as we advance towards profitability.... More